Tubulis has raised €308 million in a Series C funding round, marking the largest financing for a European biotechnology company focused on ADC development.

Target Information

Tubulis, a German biotechnology firm based in Munich, has successfully raised €308 million (equivalent to USD 361 million) in its latest funding round. This financing represents the largest Series C funding ever recorded for a European biotechnology company, as well as the most substantial financing for a private Antibody-Drug Conjugate (ADC) developer on a global scale. The funds will primarily be allocated towards advancing the clinical development of Tubulis' lead ADC candidate, known as Tub-040, while also allowing the company to expand its pipeline of innovative therapies.

The Series C round featured a robust participation from a diverse group of investors, combining both new entrants and existing stakeholders. Notably, Venrock Healthcare Capital Partners spearheaded the funding, alongside contributions from Wellington Management, Ascenta Capital, and several existing investors, including Nextech Invest, EQT Life Sciences, and Frazier Life Sciences, among others. This level of investment underscores Tubulis' strategic positioning in the competitive biotechnology landscape, particularly in the ADC sector.

Industry Overview in Germany

Germany's biotechnology sector is recognized as one of the strongest in Europe, characterized by a vibrant ecosystem that fosters innovation and R&D. The industry benefits from substantial public and private investment, a strong network of research instituti